About this trial
Intraoperative neurophysiologic monitoring (IONM) is commonly used during complex spinal surgery to monitor the integrity of neural structures and improve the perioperative safety profile. Transcranial Motor Evoked Potentials (TcMEPs) monitor the integrity of the motor pathways and are one of the most commonly used monitoring modalities in spinal surgery. Because inhaled anesthetics can negatively affect the ability to monitor TcMEPs, anesthesiologists commonly use a combination of propofol and opioids to maintain the anesthetic state. Additionally, anesthesiologists will frequently administer intravenous infusions of medications that can decrease postoperative pain and opioid use (called opioid-sparing adjuncts) because spinal surgeries result in significant postoperative pain. Despite the increasing use of these agents, there is scant clinical data about how they may affect the integrity of TcMEP monitoring. Magnesium (Mg), a N-methyl-d-aspartate receptors (NMDA) receptor antagonist, is one of the adjuncts with robust data supporting clinical efficacy to decrease pain and opioid use on TcMEPs. Mg has been used clinically for decades. The investigators commonly utilize intravenous magnesium as a component of our spinal anesthesia protocol. However, there is only a single case report that discusses the effects of Mg on TcMEPs. Here the investigators propose a prospective clinical trial to quantitatively assess the effects of various Mg plasma levels on TcMEPs. There is a lack of literature on the pharmacokinetics of magnesium in non-pregnant patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Patients with a history of significant cardiac disease (LVEF <35%, 2nd/3rd-degree block without a pacemaker, or significant arrhythmia)
Patients with kidney disease (GFR <30), or hepatic dysfunction (history of cirrhosis)
Allergy or sensitivity to magnesium
Patient with neuromuscular disease such as myasthenia graves
Trial design
Parallel
Treatments tested in this trial
Magnesium sulfate administration
DrugA single intravenous bolus of Mg of 30mg/kg (based on ideal body weight) will be administered over a period of 10 minutes (min). Control group will not have any Mg administration
Treatment groups
Trial outcomes
Primary outcomes
Serum Magnesium level
Serum magnesium level will be measured by UCSF Lab.
Magnesium- Pharmakokinetics Clearance (CL)
Serum magnesium level will be measured by UCSF Lab. Then the investigators will run the Pharmakokinetics clearance (CL) data with the levels.
Magnesium- Pharmacokinetics central volume of distribution (Vc)
Serum magnesium level will be measured by UCSF Lab. Then the investigators will run the Pharmacokinetics Central volume of distribution (Vc) data with the levels.
Magnesium- Pharmakokinetics (PK) intercompartmental clearance (Q)
Serum magnesium level will be measured by UCSF Lab. Then the investigators will run the PK intercompartmental clearance (Q) data with the levels.
Secondary outcomes
Neuromonitoring data-Stimulation voltage
The investigators will change in stimulation voltage in different time points using the students t-test
Neuromonitoring data- motor-evoked potential (MEP) amplitude
The investigators will compare motor-evoked potential (MEP) amplitude responses at different time points using the students t-test.
Neuromonitoring data- Motor Evoked Potential (MEP) Latency
The investigators will compare the change in MEP latency using the students t-test
Sponsors and contacts
Click on the lead sponsor to view all of their trials.